Skip to main content

Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) & Signal Identification

Basic Details
Status
Ongoing
Last Updated
Friday, August 22, 2025
Original Posting Date
Health Outcome(s)
signal identification
Purpose
Signal Identification
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (1)
Outcome Monitoring Following Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Use: A Self-Controlled Risk Interval Signal Identification Analysis
Result(s) (3)
Utilization of Biktarvy, Odefsey, Symtuza, and Genvoya: A Descriptive Analysis Outcome Monitoring Following Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Use: A Self-Controlled Risk Interval Signal Identification Analysis Proportion of Incident Syndrome of Inappropriate Antidiuretic Hormone Secretion Cases with Evidence of Pulmonary Opportunistic Infections Among New Users of BIC/TC/TAF: A Descriptive Analysis